Proteins differentially expressed in human beta-cells-enriched pancreatic islet cultures and human insulinomas

Molecular and Cellular Endocrinology

Volumn 381, Issue 1-2, 2013, Pages 16-25

  Terra, Letícia F ^a   Teixeira, Priscila C ^a   Wailemann, Rosangela A M ^a   Zelanis, André ^b   Palmisano, Giuseppe ^a,c   Cunha Neto, Edecio ^a   Kalil, Jorge ^a   Larsen, Martin R ^c   Labriola, Leticia ^a   Sogayar, Mari C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO BUTANTAN   (Brazil)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Diabetes; Insulinomas; Islets; Mammalian biology; Mass spectrometry; Pancreatic cell biology

Indexed keywords

CALDESMON; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MELANOMA ANTIGEN 2; PROTEOME;

ADULT; ARTICLE; CELL ADHESION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOSKELETON; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULINOMA; NUCLEOTIDE SEQUENCE; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; SIGNAL TRANSDUCTION;

CALD1; CALDESMON; DIABETES; INSULINOMAS; ISLETS; MAGE-A2; MAMMALIAN BIOLOGY; MASS SPECTROMETRY; MELANOMA ASSOCIATED ANTIGEN-A2; NR6A1; NUCLEAR RECEPTOR SUBFAMILY 6 GROUP A MEMBER 1; OTU DOMAIN-CONTAINING PROTEIN 7A; OTUD7A; PANCREATIC CELL BIOLOGY;

ADULT; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; HUMANS; INSULIN-SECRETING CELLS; INSULINOMA; MELANOMA-SPECIFIC ANTIGENS; MIDDLE AGED; PRIMARY CELL CULTURE; PROTEOME; TISSUE CULTURE TECHNIQUES; TUMOR CELLS, CULTURED; TWO-DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS;

EID: 84882738287     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2013.07.004     Document Type: Article

References (96)

1. Adams J.M., Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998, 281:1322-1326.
2. Adcock K., Austin M., Duckworth W.C., Solomon S.S., Murrell L.R. Human islet cell adenoma: metabolic analysis of the patient and of tumor cells in monolayer culture. Diabetologia 1975, 11:527-534.
3. Agoulnik I.Y., Cho Y., Niederberger C., Kieback D.G., Cooney A.J. Cloning, expression analysis and chromosomal localization of the human nuclear receptor gene GCNF. FEBS Lett. 1998, 424:73-78.
4. Aitken A. 14-3-3 proteins: a historic overview. Semin. Cancer Biol. 2006, 16:162-172.
5. Boden G. Glucagonomas and insulinomas. Gastroenterol. Clin. North Am. 1989, 18:831-845.
6. Broder L.E., Carter S.K. Pancreatic islet cell carcinoma. I. Clinical features of 52 patients. Ann. Intern. Med. 1973, 79:101-107.
7. Buchanan K.D., Johnston C.F., O'Hare M.M., Ardill J.E., Shaw C., Collins J.S., et al. Neuroendocrine tumors. A European view. Am. J. Med. 1986, 81:14-22.
8. Chen F., Cooney A.J., Wang Y., Law S.W., O'Malley B.W. Cloning of a novel orphan receptor (GCNF) expressed during germ cell development. Mol. Endocrinol. 1994, 8:1434-1444.
9. Chiang C.W., Kanies C., Kim K.W., Fang W.B., Parkhurst C., Xie M., et al. Protein phosphatase 2A dephosphorylation of phosphoserine 112 plays the gatekeeper role for BAD-mediated apoptosis. Mol. Cell. Biol. 2003, 23:6350-6362.
10. Chomez P., De Backer O., Bertrand M., De Plaen E., Boon T., Lucas S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res. 2001, 61:5544-5551.
11. Dash-Wagh S., Neumann J.R., Veitinger S., Grote-Westrick C., Landgraf P., Pape H.C., et al. The survival promoting peptide Y-P30 promotes cellular migration. Mol. Cell. Neurosci. 2011, 48:195-204.
12. De Plaen E., Arden K., Traversari C., Gaforio J.J., Szikora J.P., De Smet C., et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 1994, 40:360-369.
13. De Smet C., Courtois S.J., Faraoni I., Lurquin C., Szikora J.P., De Backer O., et al. Involvement of two Ets binding sites in the transcriptional activation of the MAGE1 gene. Immunogenetics 1995, 42:282-290.
14. De Smet C., Loriot A., Boon T. Promoter-dependent mechanism leading to selective hypomethylation within the 5' region of gene MAGE-A1 in tumor cells. Mol. Cell. Biol. 2004, 24:4781-4790.
15. Dong H., Woo S.L. Hepatic insulin production for type 1 diabetes. Trends Endocrinol. Metab. 2001, 12:441-446.
16. Duan Z., Duan Y., Lamendola D.E., Yusuf R.Z., Naeem R., Penson R.T., et al. Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin. Cancer Res. 2003, 9:2778-2785.
17. Eizirik D., Sandler S., Welsh N., Cetkovic-Cvrlje M., Nieman A., Geller D., et al. Cytokines suppress human islet function irrespective of their effects on nitric oxide generation. J. Clin. Invest. 1994, 93:1968-1974.
18. Eizirik D.L., Flodstrom M., Karlsen A.E., Welsh N. The harmony of the spheres: inducible nitric oxide synthase and related genes in pancreatic beta cells. Diabetologia 1996, 39:875-890.
19. Eizirik D., Colli M., Ortis F. The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat. Rev. Endocrinol. 2009, 5:219-226.
20. Eves R., Webb B.A., Zhou S., Mak A.S. Caldesmon is an integral component of podosomes in smooth muscle cells. J. Cell Sci. 2006, 119:1691-1702.
21. Fan T., Li R., Todd N.W., Qiu Q., Fang H.B., Wang H., et al. Up-regulation of 14-3-3zeta in lung cancer and its implication as prognostic and therapeutic target. Cancer Res. 2007, 67:7901-7906.
22. Frodin M., Sekine N., Roche E., Filloux C., Prentki M., Wollheim C.B., et al. Glucose, other secretagogues, and nerve growth factor stimulate mitogen-activated protein kinase in the insulin-secreting beta-cell line, INS-1. J. Biol. Chem. 1995, 270:7882-7889.
23. Gartner W., Koc F., Nabokikh A., Daneva T., Niederle B., Luger A., et al. Long-term in vitro growth of human insulin-secreting insulinoma cells. Neuroendocrinology 2006, 83:123-130.
24. Ghosh R., Karmohapatra S.K., Bhattacharyya M., Bhattacharya R., Bhattacharya G., Sinha A.K. The appearance of dermcidin isoform 2, a novel platelet aggregating agent in the circulation in acute myocardial infarction that inhibits insulin synthesis and the restoration by acetyl salicylic acid of its effects. J. Thromb. Thrombolysis 2011, 31:13-21.
25. Gragnoli C. The CM Cell line derived from liver metastasis of malignant human insulinoma is not a valid beta cell model for in vitro studies. J. Cell. Physiol. 2008, 216:569-570.
26. Greenberg M.J., Wang C.L., Lehman W., Moore J.R. Modulation of actin mechanics by caldesmon and tropomyosin. Cell Motil. Cytoskel. 2008, 65:156-164.
27. Gu Z., Kordowska J., Williams G.L., Wang C.L., Hai C.M. Erk1/2 MAPK and caldesmon differentially regulate podosome dynamics in A7r5 vascular smooth muscle cells. Exp. Cell Res. 2007, 313:849-866.
28. 2+ in clonal insulin-releasing cells. Evidence for an opposing effect of muscarinic-receptor activation. Biochem. J. 1986, 233:865-870.
29. Hai C.M., Gu Z. Caldesmon phosphorylation in actin cytoskeletal remodeling. Eur. J. Cell Biol. 2006, 85:305-309.
30. Hay C.W., Docherty K. Comparative analysis of insulin gene promoters: implications for diabetes research. Diabetes 2006, 55:3201-3213.
31. Henquin J.C. Effects of trifluoperazine and pimozide on stimulus-secretion coupling in pancreatic B-cells. Suggestion for a role of calmodulin?. Biochem. J. 1981, 196:771-780.
32. Hill R.S., Oberwetter J.M., Boyd A.E. Increase in cAMP levels in beta-cell line potentiates insulin secretion without altering cytosolic free-calcium concentration. Diabetes 1987, 36:440-446.
33. Huber P.A. Caldesmon. Int. J. Biochem. Cell. Biol. 1997, 29:1047-1051.
34. Inoue H., Li J., Honda M., Nakashima H., Shibuta K., Arinaga S., et al. MAGE-1 mRNA expression in gastric carcinoma. Int. J. Cancer 1995, 64:76-77.
35. Kaczirek K., Soleiman A., Schindl M., Passler C., Scheuba C., Prager G., et al. Nesidioblastosis in adults: a challenging cause of organic hyperinsulinism. Eur. J. Clin. Invest. 2003, 33:488-492.
36. Katz D., Niederberger C., Slaughter G.R., Cooney A.J. Characterization of germ cell-specific expression of the orphan nuclear receptor, germ cell nuclear factor. Endocrinology 1997, 138:4364-4372.
37. Kayagaki N., Phung Q., Chan S., Chaudhari R., Quan C., O'Rourke K.M., et al. DUBA: a deubiquitinase that regulates type I interferon production. Science 2007, 318:1628-1632.
38. Keller A., Eng J., Zhang N., Li X.J., Aebersold R. A uniform proteomics MS/MS analysis platform utilizing open XML file formats. Mol. Syst. Biol. 2005, 2005(1):0017.
39. Kido Y., Burks D.J., Withers D., Bruning J.C., Kahn C.R., White M.F., et al. Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. J. Clin. Invest. 2000, 105:199-205.
40. Kilani R.T., Maksymowych W.P., Aitken A., Boire G., St-Pierre Y., Li Y., et al. Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation. J. Rheumatol. 2007, 34:1650-1657.
41. Koganehira Y., Takeoka M., Ehara T., Sasaki K., Murata H., Saida T., et al. Reduced expression of actin-binding proteins, h-caldesmon and calponin h1, in the vascular smooth muscle inside melanoma lesions: an adverse prognostic factor for malignant melanoma. Br. J. Dermatol. 2003, 148:971-980.
42. Labriola L., Ferreira G.B., Montor W.R., Demasi M.A., Pimenta D.C., Lojudice F.H., et al. Prolactin-induced changes in protein expression in human pancreatic islets. Mol. Cell. Endocrinol. 2007, 264:16-27.
43. Labriola L., Peters M.G., Krogh K., Stigliano I., Terra L.F., Buchanan C., et al. Generation and characterization of human insulin-releasing cell lines. BMC Cell Biol. 2009, 10.
44. Lan Z.J., Xu X., Chung A.C., Cooney A.J. Extra-germ cell expression of mouse nuclear receptor subfamily 6, group A, member 1 (NR6A1). Biol. Reprod. 2009, 80:905-912.
45. Lee Motoyama J.P., Kim-Motoyama H., Kim P., Nakagama H., Miyagawa K., Suzuki K. Identification of dermcidin in human gestational tissue and characterization of its proteolytic activity. Biochem. Biophys. Res. Commun. 2007, 357:828-833.
46. Li Z., Zhao J., Du Y., Park H.R., Sun S.Y., Bernal-Mizrachi L., et al. Down-regulation of 14-3-3zeta suppresses anchorage-independent growth of lung cancer cells through anoikis activation. Proc. Natl. Acad. Sci. USA 2008, 105:162-167.
47. Liang G., Gonzales F.A., Jones P.A., Orntoft T.F., Thykjaer T. Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2'-deoxycytidine. Cancer Res. 2002, 62:961-966.
48. MacFarlane W.M., Chapman J.C., Shepherd R.M., Hashmi M.N., Kamimura N., Cosgrove K.E., et al. Engineering a glucose-responsive human insulin-secreting cell line from islets of Langerhans isolated from a patient with persistent hyperinsulinemic hypoglycemia of infancy. J. Biol. Chem. 1999, 274:34059-34066.
49. Machado M.C., Jukemura J., da Cunha J.E., Penteado S., Bacchella T., Abdo E.E., et al. Surgical treatment of insulinoma: study of 59 cases. Rev. Assoc. Med. Bras. 1998, 44:159-166.
50. Maria-Engler S.S., Correa-Giannella M.L., Labriola L., Krogh K., Colin C., Lojudice F.H., et al. Co-localization of nestin and insulin and expression of islet cell markers in long-term human pancreatic nestin-positive cell cultures. J. Endocrinol. 2004, 183:455-467.
51. Maslyar D.J., Aoki M., Vogt P.K. The growth-promoting activity of the bad protein in chicken embryo fibroblasts requires binding to protein 14-3-3. Oncogene 2001, 20:5087-5092.
52. Masters S.C., Fu H. 14-3-3 Proteins mediate an essential anti-apoptotic signal. J. Biol. Chem. 2001, 276:45193-45200.
53. Meglasson M.D., Manning C.D., Najafi H., Matschinsky F.M. Glucose transport by radiation-induced insulinoma and clonal pancreatic beta-cells. Diabetes 1986, 35:1340-1344.
54. Menegaux F., Schmitt G., Mercadier M., Chigot J.P. Pancreatic insulinomas. Am. J. Surg. 1993, 165:243-248.
55. Monte M., Simonatto M., Peche L.Y., Bublik D.R., Gobessi S., Pierotti M.A., et al. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc. Natl. Acad. Sci. USA 2006, 103:11160-11165.
56. Morita T., Mayanagi T., Yoshio T., Sobue K. Changes in the balance between caldesmon regulated by p21-activated kinases and the Arp2/3 complex govern podosome formation. J. Biol. Chem. 2007, 282:8454-8463.
57. Mukamal K.J., Mittleman M.A., Maclure M., Sherwood J.B., Goldberg R.J., Muller J.E. Recent aspirin use is associated with smaller myocardial infarct size and lower likelihood of Q-wave infarction. Am. Heart J. 1999, 137:1120-1128.
58. Mukhopadhyay U.K., Eves R., Jia L., Mooney P., Mak A.S. P53 suppresses Src-induced podosome and rosette formation and cellular invasiveness through the upregulation of caldesmon. Mol. Cell. Biol. 2009, 29:3088-3098.
59. Nielsen K., Karlsen A.E., Deckert M., Madsen O.D., Serup P., Mandrup-Poulsen T., et al. Beta-cell maturation leads to in vitro sensitivity to cytotoxins. Diabetes 1999, 48:2324-2332.
60. Nielsen K., Sparre T., Larsen M.R., Nielsen M., Fey S.J., Mose Larsen P., et al. Protein expression changes in a cell system of beta-cell maturation reflect an acquired sensitivity to IL-1beta. Diabetologia 2004, 47:62-74.
61. Novy R.E., Lin J.L., Lin J.J. Characterization of cDNA clones encoding a human fibroblast caldesmon isoform and analysis of caldesmon expression in normal and transformed cells. J. Biol. Chem. 1991, 266:16917-16924.
62. Oberg K., Eriksson B. Endocrine tumours of the pancreas. Best Pract. Res. Clin. Gastroenterol. 2005, 19:753-781.
63. Ortis F., Pirot P., Naamane N., Kreins A.Y., Rasschaert J., Moore F., et al. Induction of nuclear factor-kappaB and its downstream genes by TNF-alpha and IL-1beta has a pro-apoptotic role in pancreatic beta cells. Diabetologia 2008, 51:1213-1225.
64. Ortis F., Naamane N., Flamez D., Ladriere L., Moore F., Cunha D., et al. Cytokines interleukin-1beta and tumor necrosis factor-alpha regulate different transcriptional and alternative splicing networks in primary beta-cells. Diabetes 2010, 59:358-374.
65. Owada M.K., Hakura A., Iida K., Yahara I., Sobue K., Kakiuchi S. Occurrence of caldesmon (a calmodulin-binding protein) in cultured cells: comparison of normal and transformed cells. Proc. Natl. Acad. Sci. USA 1984, 81:3133-3137.
66. Porter D., Weremowicz S., Chin K., Seth P., Keshaviah A., Lahti-Domenici J., et al. A neural survival factor is a candidate oncogene in breast cancer. Proc. Natl. Acad. Sci. USA 2003, 100:10931-10936.
67. Porter G.W., Khuri F.R., Fu H. Dynamic 14-3-3/client protein interactions integrate survival and apoptotic pathways. Semin. Cancer Biol. 2006, 16:193-202.
68. Proye C. Surgical strategy in insulinoma of adults. Clinical review. Acta Chir. Scand. 1987, 153:481-491.
69. Qi W., Liu X., Qiao D., Martinez J.D. Isoform-specific expression of 14-3-3 proteins in human lung cancer tissues. Int. J. Cancer 2005, 113:359-363.
70. Ricordi C., Lacy P.E., Finke E.H., Olack B.J., Scharp D.W. Automated method for isolation of human pancreatic islets. Diabetes 1988, 37:413-420.
71. Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P., et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 2000, 24:227-235.
72. Schittek B. The multiple facets of Dermcidin in cell survival and host defense. J. Innate Immun. 2012.
73. Schittek B., Hipfel R., Sauer B., Bauer J., Kalbacher H., Stevanovic S., et al. Dermcidin: a novel human antibiotic peptide secreted by sweat glands. Nat. Immunol. 2001, 2:1133-1137.
74. Schittek B., Paulmann M., Senyurek I., Steffen H. The role of antimicrobial peptides in human skin and in skin infectious diseases. Infect. Disord. Drug Targets 2008, 8:135-143.
75. Shapiro M.E., Liu M. Prolongation of islet allograft survival by anti-CD45 antibody pretreatment. Transplant. Proc. 1995, 27:613-614.
76. Shen S.L., Qiu F.H., Dayarathna T.K., Wu J., Kuang M., Li S.S., et al. Identification of Dermcidin as a novel binding protein of Nck1 and characterization of its role in promoting cell migration. Biochim. Biophys. Acta 2011, 1812:703-710.
77. Sobue K., Sellers J.R. Caldesmon, a novel regulatory protein in smooth muscle and nonmuscle actomyosin systems. J. Biol. Chem. 1991, 266:12115-12118.
78. Subramanian R.R., Masters S.C., Zhang H., Fu H. Functional conservation of 14-3-3 isoforms in inhibiting bad-induced apoptosis. Exp. Cell Res. 2001, 271:142-151.
79. Sugden M.C., Christie M.R., Ashcroft S.J. Presence and possible role of calcium-dependent regulator (calmodulin) in rat islets of Langerhans. FEBS Lett. 1979, 105:95-100.
80. Tanaka J., Watanabe T., Nakamura N., Sobue K. Morphological and biochemical analyses of contractile proteins (actin, myosin, caldesmon and tropomyosin) in normal and transformed cells. J. Cell Sci. 1993, 104(Pt 2):595-606.
81. Toyo-oka K., Shionoya A., Gambello M.J., Cardoso C., Leventer R., Ward H.L., et al. 14-3-3Epsilon is important for neuronal migration by binding to NUDEL: a molecular explanation for Miller-Dieker syndrome. Nat. Genet. 2003, 34:274-285.
82. Trautmann M.E., Wollheim C.B. Characterization of glucose transport in an insulin-secreting cell line. Biochem. J. 1987, 242:625-630.
83. Tucker O.N., Crotty P.L., Conlon K.C. The management of insulinoma. Br. J. Surg. 2006, 93:264-275.
84. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254:1643-1647.
85. Verspohl E.J., Tollkuhn B., Kloss H. Role of tyrosine kinase in insulin release in an insulin secreting cell line (INS-1). Cell Signal. 1995, 7:505-512.
86. Wang X.C., Xu S.Y., Wu X.Y., Song H.D., Mao Y.F., Fan H.Y., et al. Gene expression profiling in human insulinoma tissue: genes involved in the insulin secretion pathway and cloning of novel full-length cDNAs. Endocrinol. Relat. Cancer 2004, 11:295-303.
87. Watkins D., White B.A. Identification and characterization of calmodulin-binding proteins in islet secretion granules. J. Biol. Chem. 1985, 260:5161-5165.
88. Wiesner J., Vilcinskas A. Antimicrobial peptides: the ancient arm of the human immune system. Virulence 2010, 1:440-464.
89. Wilker E., Yaffe M.B. 14-3-3 Proteins - a focus on cancer and human disease. J. Mol. Cell. Cardiol. 2004, 37:633-642.
90. DC and CTR group, 1993. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl. J. Med. 329, 977-986.
91. Yamashiro S., Yamakita Y., Ishikawa R., Matsumura F. Mitosis-specific phosphorylation causes 83K non-muscle caldesmon to dissociate from microfilaments. Nature 1990, 344:675-678.
92. Yamashiro S., Yamakita Y., Hosoya H., Matsumura F. Phosphorylation of non-muscle caldesmon by p34cdc2 kinase during mitosis. Nature 1991, 349:169-172.
93. Yang H., Masters S.C., Wang H., Fu H. The proapoptotic protein bad binds the amphipathic groove of 14-3-3zeta. Biochim. Biophys. Acta 2001, 1547:313-319.
94. Yoshio T., Morita T., Kimura Y., Tsujii M., Hayashi N., Sobue K. Caldesmon suppresses cancer cell invasion by regulating podosome/invadopodium formation. FEBS Lett. 2007, 581:3777-3782.
95. Zang D., Li X., Zhang L. 14-3-3zeta Overexpression and abnormal beta-catenin expression are associated with poor differentiation and progression in stage I non-small cell lung cancer. Clin. Exp. Med. 2010, 10:221-228.
96. Zha J., Harada H., Yang E., Jockel J., Korsmeyer S.J. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 1996, 87:619-628.